NASDAQ$NXTC
NextCure Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
NextCure reported third quarter 2022 financial results and discontinued development of NC318 program.
NextCure reported its third quarter 2022 financial results, highlighted by the discontinuation of the NC318 program and the extension of the cash runway into mid-2025. The company is focusing on advancing its clinical pipeline, including NC410, NC525, and NC762.
- Discontinued clinical development of NC318 based on efficacy data.
- Initiated a Phase 1b/2 trial to evaluate NC410 in combination with pembrolizumab in patients with solid tumors.
- Filed an Investigational New Drug (IND) application for NC525 and received clearance to proceed with a Phase 1 trial.
- Initiated the NC762 expansion trial.
Headline financials
Revenue & EPS history
NextCure · Revenue · Quarterly
$0
Forward guidance
NextCure expects that discontinuing NC318 and prioritizing NC410 will extend its cash runway into mid-2025, enabling the company to fund operating expenses and capital expenditures.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+0.7%
Avg return
Earnings day
+1.0%
Avg return
5 days after
-1.4%
Avg return
30 days after
36%
10 / 28 earnings
Positive
+34.8%
Q4 2023
Best reaction
-19.8%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.9% | +6.6% | -16.0% | |
| Q3 2025 | -8.8% | -5.4% | +25.6% | |
| Q2 2025 | -4.4% | +1.9% | -4.8% | |
| Q2 2024 | -1.2% | +1.9% | -4.8% | |
| Q1 2025 | -7.7% | -20.8% | +2.5% | |
| Q4 2024 | +6.1% | -1.7% | -37.7% | |
| Q3 2024 | -1.5% | +18.0% | -12.6% | |
| Q1 2024 | +11.7% | +15.3% | +12.4% | |
| Q4 2023 | +34.8% | +39.7% | +13.5% | |
| Q3 2023 | +10.3% | +6.5% | +12.1% | |
| Q2 2023 | -2.9% | -2.3% | -18.9% | |
| Q1 2023 | +4.6% | +14.5% | +14.5% | |
| Q4 2022 | -4.5% | -5.1% | -5.7% | |
| Q3 2022 | -19.8% | -31.2% | -42.9% | |
| Q2 2022 | +9.8% | +14.0% | -5.1% | |
| Q1 2022 | -4.5% | -15.1% | +4.8% | |
| Q4 2021 | -1.4% | +0.4% | +2.7% | |
| Q3 2021 | -1.4% | -23.5% | -34.5% | |
| Q2 2021 | +5.8% | +3.2% | +7.5% | |
| Q1 2021 | +3.4% | +5.0% | -1.0% | |
| Q4 2020 | -2.0% | +2.1% | -12.7% | |
| Q3 2020 | -4.3% | +0.9% | +11.0% | |
| Q2 2020 | -1.3% | -3.1% | -14.2% | |
| Q1 2020 | +12.2% | +4.0% | -24.8% | |
| Q4 2019 | -12.3% | +4.0% | +5.2% | |
| Q3 2019 | -3.3% | -7.6% | +31.3% | |
| Q2 2019 | +11.7% | +11.1% | +53.9% | |
| Q1 2019 | -6.8% | -6.3% | +0.5% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro